Jinxin Fertility Group Ltd. (1951) AI Stock Analysis

• Market Cap: HK$8.64B
• Dividend Yield: 1.99%
• Average Volume (3M): 108.86M
• Price to Earnings (P/E): 27.5
• Beta (1Y): 1.41
• Revenue Growth: -1.04%
• EPS Growth: -20.43%
• Country: HK
• Employees: 3,198
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 2,757,706,000
• 10 Day Avg. Volume: 88,273,085
• 30 Day Avg. Volume: 108,855,540
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.50
• Price Target Upside: 11.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: HK$3.50 ▲(11.11% Upside)

Jinxin Fertility Group's strong financial performance is the most significant factor, supported by consistent revenue growth and solid profitability. Technical analysis shows a positive trend, although momentum is limited. The valuation suggests the stock may be overvalued, which slightly offsets the positive financial performance.

Jinxin Fertility Group Ltd. Business Overview & Revenue Model

Company Description

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

How the Company Makes Money

Jinxin Fertility Group Ltd. generates revenue primarily through the provision of fertility treatment services. The company's key revenue streams include fees collected for various assisted reproductive technologies, such as IVF procedures, fertility consultations, and pre-implantation genetic testing. Additionally, the company may derive income from related healthcare services and the sale of pharmaceuticals and medical equipment used in fertility treatments. Strategic partnerships with hospitals and research institutions further enhance its market position and contribute to its earnings by expanding service offerings and improving treatment outcomes.

Jinxin Fertility Group Ltd. Financial Statement Overview

Summary

Jinxin Fertility Group demonstrates a strong financial position with consistent revenue growth, solid profitability, and efficient cash flow management. The balance sheet shows prudent leverage and strong equity, while operational efficiency is reflected in healthy margins and cash flow metrics. Continued focus on cost management and cash generation will further strengthen its financial performance.

Income Statement

Jinxin Fertility Group has shown consistent revenue growth over the years, with a notable increase in total revenue from 2020 to 2024. The gross profit margin has slightly decreased recently, indicating rising costs or pricing pressures. However, the company maintains healthy EBIT and EBITDA margins, demonstrating efficient operations and profitability.

Balance Sheet

The company has a strong equity base with a favorable debt-to-equity ratio, indicating prudent financial leverage. The return on equity remains strong, reflecting effective use of shareholders' funds. The equity ratio has increased over the years, highlighting a solid financial foundation and asset management.

Cash Flow

Operating cash flow has been positive and growing, supporting ongoing operations. The free cash flow, although fluctuating, has improved recently, enhancing financial flexibility. The operating cash flow to net income ratio is robust, indicating strong cash earnings conversion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.81B	2.79B	2.36B	1.84B	1.43B
Gross Profit	1.10B	1.18B	913.13M	771.48M	565.78M
EBITDA	645.06M	682.02M	476.21M	494.08M	331.91M
Net Income	283.10M	344.72M	121.12M	339.90M	251.62M
Balance Sheet
Total Assets	14.98B	14.90B	15.23B	12.83B	9.16B
Cash, Cash Equivalents and Short-Term Investments	570.82M	852.90M	1.40B	1.93B	2.47B
Total Debt	2.71B	2.55B	4.16B	2.09B	406.87M
Total Liabilities	4.63B	4.71B	6.50B	4.07B	1.70B
Stockholders Equity	10.27B	10.09B	8.64B	8.55B	7.28B
Cash Flow
Free Cash Flow	489.30M	510.92M	-417.65M	263.62M	41.89M
Operating Cash Flow	629.20M	684.48M	541.74M	343.45M	308.04M
Investing Cash Flow	-293.27M	-375.04M	-1.38B	-1.57B	1.15B
Financing Cash Flow	-458.29M	-950.45M	460.14M	955.05M	-55.58M

Jinxin Fertility Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 3.15 is below the 20-day moving average (MA) of 3.19, above the 50-day MA of 3.06, and above the 200-day MA of 2.95, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 53.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.

Jinxin Fertility Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2373	76 Outperform	HK$7.07B	27.88	26.24%	1.68%	17.69%	5.37%
6078	70 Outperform	HK$9.89B	15.61	9.30%	―	7.28%	-13.77%
1951	69 Neutral	HK$8.64B	27.51	2.78%	1.99%	-1.04%	-20.43%
1526	66 Neutral	HK$1.73B	5.38	24.13%	4.17%	-3.85%	-19.28%
2273	63 Neutral	HK$7.89B	24.43	13.13%	1.22%	28.02%	19.41%
3309	54 Neutral	HK$2.37B	33.92	-7.51%	1.06%	-0.56%	-323.09%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%

Jinxin Fertility Group Ltd. Corporate Events

Jinxin Fertility Group Announces Profit Warning and CFO Appointment

Jinxin Fertility Group Ltd. has issued a profit warning, anticipating a loss of up to RMB1,090 million for the first half of 2025, primarily due to impairments and provisions related to its operations in the United States and Laos. Despite these challenges, the company remains confident in its long-term growth prospects, citing strong industry foundations and supportive national policies. Additionally, the company has appointed Mr. Dong Yang as the acting chief financial officer, who will oversee financial management and business development.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Announces Board Composition and Governance Structure

Jinxin Fertility Group Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board is structured with executive, non-executive, and independent non-executive directors, and has established five committees to oversee various aspects of the company’s operations. This announcement underscores the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its position in the competitive fertility industry.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Schedules Board Meeting to Review Interim Results

Jinxin Fertility Group Limited has announced a scheduled board meeting on August 25, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market positioning.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Ltd. Announces AGM Results and Committee Changes

Jinxin Fertility Group Ltd. held its Annual General Meeting on June 26, 2025, where all proposed resolutions were approved by poll. Key resolutions included the adoption of the company’s audited financial statements for 2024, re-election of several directors, and the re-appointment of Deloitte Touche Tohmatsu as the company’s auditor. These decisions reflect the company’s ongoing commitment to maintaining strong governance and financial transparency, which are crucial for its stakeholders and market positioning.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Announces Board Composition and Roles

Jinxin Fertility Group Limited has announced the composition of its board of directors and the roles and functions of each member. The board includes executive, non-executive, and independent non-executive directors, with various members serving on five established committees. This announcement reflects the company’s structured governance approach and may impact its strategic decision-making and operational oversight.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.

Jinxin Fertility Group Announces 2025 Annual General Meeting

Jinxin Fertility Group Ltd. has announced its upcoming annual general meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as auditors. Additionally, the company seeks shareholder approval to authorize the board to issue new shares and fix director remuneration, indicating a focus on strategic growth and governance.

The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.33 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.